Abstract
Sublingual immunotherapy for Japanese cedar pollinosis: potential biomarkers predicting therapeutic responses
Highlights
Allergic rhinitis/pollinosis was first reported by Blackley [1] in 1873
During the 90-day period from February 1 to April 30, the sneezing score, nasal itching score, rhinorrhea score, nasal congestion score, and total nasal symptom score (TNSS) were significantly lower in the Sublingual immunotherapy (SLIT) group than the placebo group for 15, 15, 33, 22, and 37 days, respectively
Serum levels of Japanese cedar (JC) allergen-specific IgG and IgE showed no significant difference between the 2 groups before treatment, but were significantly higher in the SLIT group than the placebo group after the pollen season
Summary
Allergic rhinitis/pollinosis (hay fever) was first reported by Blackley [1] in 1873. In Japan, Saito [2] first reported Japanese cedar (JC) pollinosis in 1964, and it subsequently increased owing to large-scale planting of cedar trees during the 1970s. A survey performed in 2008 showed that the prevalence of JC pollinosis was 26.5% in Japan [3], making it the major allergic disease affecting the Japanese population. Noon initially reported the effectiveness of immunotherapy for allergy in 1911[4]. Immunotherapy for allergic diseases has subsequently attracted considerable attention in many countries including Japan. In the 1960s, a pollen-specific antigen extract became available for immunotherapy in Japan and a standardized cedar antigen-specific extract was released in 2000
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
